CETO for Primary Aldosteronism

Phase-Based Progress Estimates
University of Calgary, Calgary, Canada
Primary Aldosteronism+1 More
[18-F]CETO - Biological
All Sexes
What conditions do you have?

Study Summary

This study is to evaluate the accuracy of a novel radiopharmaceutical tracer, para-chloro-2-[18F]fluoroethyl etomidate (CETO), used with positron emission tomography (PET) and computed tomography (CT), as a way to subtype unilateral vs. bilateral forms of Primary Aldosteronism, compared to AVS as a reference gold standard.

Eligible Conditions

  • Primary Aldosteronism

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: It will be measured using adrenal vein sampling approximately the same time as the CETO PET/CT.

It will be measured using adrenal vein sampling approximately the same time as the CETO PET/CT.
The measure is diagnostic test accuracy (expressed as sensitivity, specificity, positive predictive value, and negative predictive value) for CETO PET/CT using adrenal vein sampling as a reference standard.

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: CETO · No Placebo Group · Phase 2

Experimental Group · 1 Intervention: [18-F]CETO · Intervention Types: Biological

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: it will be measured using adrenal vein sampling approximately the same time as the ceto pet/ct.
Closest Location: University of Calgary · Calgary, Canada
Photo of Calgary  1Photo of Calgary  2Photo of Calgary  3
2004First Recorded Clinical Trial
2 TrialsResearching Primary Aldosteronism
270 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Individuals with an elevated ARR have a higher risk of having an abnormal cortisol profile.
Individuals with or without spontaneous or diuretic-induced hypokalemia, and/ or plus a discrete adrenal nodule or nodules (1 cm or greater) with concordant lateralization on AVS.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.